Wang Q, Bryan R M, Pelligrino D A
Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL 60607, USA.
Brain Res. 1998 May 18;793(1-2):187-96. doi: 10.1016/s0006-8993(98)00173-5.
The conclusion that cyclic 3'-5 guanosine monophosphate (cGMP) functions in a 'permissive' manner in promoting cerebrovasodilation during hypercapnia was based on findings showing that the nitric oxide synthase (NOS) inhibitor-induced repression of the CO2 response could be reversed upon addition of exogenous cGMP. We hypothesized that the action of cGMP revealed in those studies does not define its normal role in hypercapnic cerebral vasodilation, but rather is a unique function of the artificial situation of NOS inhibition coupled with cGMP repletion. Thus, although CO2 reactivity may be the same in normal versus cGMP-repleted animals, the factors contributing to that response may differ. To test that possibility, the effects of calcium-dependent (KCa) or ATP-sensitive (KATP) potassium channel blockers on pial arteriolar CO2 reactivity, in vivo, were evaluated in the presence and absence of NOS inhibition plus administration of a cGMP analogue. Pial arteriolar diameter changes in hypercapnia were measured in three principal groups of anesthetized rats: (I) KCa channel-inhibited (via iberiotoxin); (II) KATP channel-inhibited (via glibenclamide); and (III) controls. Group I and II rats were further divided into: (a) those treated with the neuronal NOS (nNOS) inhibitor, 7-nitroindazole (7-NI), followed by successive suffusions of the cGMP analogue, 8-bromo-cGMP (8Br-cGMP) and 8Br-cGMP+K-channel blocker; and (b) rats where 7-NI and 8Br-cGMP applications were omitted. Group III rats were divided into time and 8Br-cGMP controls. Hypercapnia (PCO2 congruent with60 mmHg, 3 min)-induced dilations were reduced by 70-80% following 7-NI and restored by 8Br-cGMP. That restoration was reversed by both K-channel blockers. In the absence of 7-NI and exogenous cGMP, CO2 reactivity was unaffected by K-channel inhibition. These findings confirmed that nNOS-derived NO is critically important to the hypercapnic reactivity of cerebral arterioles, and that cGMP repletion, following NOS inhibition, could restore CO2 reactivity. The observation that KCa and KATP channel blockade did not alter CO2 reactivity under baseline conditions, but attenuated CO2 reactivity only in the presence nNOS inhibition (and cGMP repletion), suggests that multiple, redundant, and interactive mechanisms participate in CO2-induced vasodilation. These results also imply that current strategies for revealing permissive actions of cGMP (or NO) may need to be re-evaluated.
关于环磷酸鸟苷(cGMP)在高碳酸血症期间以“允许性”方式促进脑血管舒张的结论,是基于以下研究结果得出的:一氧化氮合酶(NOS)抑制剂诱导的对二氧化碳反应的抑制作用,在添加外源性cGMP后可被逆转。我们推测,这些研究中所揭示的cGMP的作用,并未界定其在高碳酸血症性脑血管舒张中的正常作用,而更像是NOS抑制与cGMP补充这种人为情况的独特功能。因此,尽管正常动物与补充cGMP的动物的二氧化碳反应性可能相同,但促成该反应的因素可能不同。为了验证这种可能性,在存在和不存在NOS抑制以及给予cGMP类似物的情况下,评估了钙依赖性(KCa)或ATP敏感性(KATP)钾通道阻滞剂对软脑膜小动脉二氧化碳反应性的体内影响。在三组主要的麻醉大鼠中测量了高碳酸血症时软脑膜小动脉直径的变化:(I)KCa通道抑制组(通过埃博毒素);(II)KATP通道抑制组(通过格列本脲);以及(III)对照组。I组和II组大鼠进一步分为:(a)用神经元型NOS(nNOS)抑制剂7-硝基吲唑(7-NI)处理,随后依次灌注cGMP类似物8-溴-cGMP(8Br-cGMP)和8Br-cGMP +钾通道阻滞剂的大鼠;以及(b)省略7-NI和8Br-cGMP应用的大鼠。III组大鼠分为时间和8Br-cGMP对照组。7-NI处理后,高碳酸血症(PCO2等于60 mmHg,3分钟)诱导的血管舒张减少了70 - 80%,而8Br-cGMP使其恢复。两种钾通道阻滞剂均可逆转这种恢复。在不存在7-NI和外源性cGMP的情况下,钾通道抑制对二氧化碳反应性无影响。这些发现证实,nNOS衍生的一氧化氮对脑小动脉的高碳酸血症反应性至关重要,并且在NOS抑制后补充cGMP可恢复二氧化碳反应性。在基线条件下,KCa和KATP通道阻断未改变二氧化碳反应性,但仅在存在nNOS抑制(和cGMP补充)的情况下减弱了二氧化碳反应性,这一观察结果表明,多种、冗余且相互作用的机制参与了二氧化碳诱导的血管舒张。这些结果还意味着,目前揭示cGMP(或一氧化氮)允许性作用的策略可能需要重新评估。